Mereo BioPharma (MREO) Common Equity (2017 - 2026)

Mereo BioPharma (MREO) has reported Common Equity for 10 consecutive years, with $28.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 47.11% year-over-year to $28.7 million in Q2 2026; TTM through Jun 2026 was $28.7 million, a 47.11% decrease from a year earlier, with the FY2025 full-year figure at $40.9 million, down 32.89% from the prior year.
• Common Equity was $28.7 million for Q2 2026 at Mereo BioPharma, down from $34.1 million in the prior quarter.
• Over five years, Common Equity peaked at $87.6 million in Q2 2022 and troughed at -$72.5 million in Q3 2024.
• A 5-year average of $45.9 million and a median of $50.1 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity plunged 232.59% in 2024 and jumped 164.24% in 2025, its largest moves.
• Over 5 years, Common Equity stood at $72.6 million in 2022, then plunged by 30.36% to $50.5 million in 2023, then advanced by 20.64% to $61.0 million in 2024, then sank by 32.89% to $40.9 million in 2025, then slipped by 29.97% to $28.7 million in 2026.
• The last three Common Equity figures came in at $28.7 million (Q2 2026), $34.1 million (Q1 2026), and $40.9 million (Q4 2025), per Business Quant data.